Venous Thromboembolism in Premature Neonates
- PMID: 34942667
- DOI: 10.1055/s-0041-1740267
Venous Thromboembolism in Premature Neonates
Abstract
While the incidence of venous thromboembolism (VTE) is lower among children than adults, the newborn period is one of two bimodal peaks (along with adolescence) in VTE incidence in the pediatric population. Most VTE cases in neonates occur among critically ill neonates being managed in the neonatal intensive care unit, and most of these children are born premature. For this reason, the presentation, diagnosis, management, and outcomes of VTE among children born premature deserve special emphasis by pediatric hematologists, neonatologists, pharmacists, and other pediatric health care providers, as well as by the scientific community, and are described in this review.
Thieme. All rights reserved.
Conflict of interest statement
P.F. reports receiving consultancy fees from Onybiotech for participation in clinical trial design and oversight committees (e.g., Steering, Advisory). M.B. reports receiving research support and salary support from the Hemophilia and Thrombosis Research Society of North America. N.A.G. reports receiving research support and salary support from the National Institutes of Health, and receives or has recently received consultancy fees from Bayer, Daiichi-Sankyo, Novartis, Anthos, and the University of Colorado-affiliated Academic Research Organization CPC Clinical Research for participation in clinical trial design and oversight committees (e.g., Steering, Advisory, and Data and Safety Monitoring). He also reports other from Bayer, outside the submitted work; and Dr. Goldenberg receives research support and salary support from the National Institutes of Health, National Heart Lung and Blood Institute for clinical and translational investigation in venous thromboembolism in patients <21 years old. He receives consultancy fees from Daiici Sankyo Inc., Anthos Therapeutics Inc., and the Academic Research Organization CPC Clinical Research for roles in clinical trial oversight committees (e.g., steering, data, and safety monitoring) in pharmaceutical industry-sponsored pediatric clinical trials of antithrombotic agents.
